In this article, we will take a look at the top 7 hidden multibagger stocks to invest in.
Multibaggers often take the limelight because of their stellar returns, but it isn’t always easy to catch these multibaggers while they are in the process of generating these returns. The market usually discovers them late, which is why we continuously look for hidden multibagger stocks to invest in.
One way to identify such stocks is to look for those quietly strengthening their finances and gaining customers or market share. Quite often, the stock price slowly creeps up as investors start betting on the company’s growth. This is why multibaggers aren’t just beaten-down stocks that will generate incredible returns when the tide turns. They’re usually the ones who are improving themselves, quarter by quarter. This is an important part of how we identify these stocks.
In the current market, it is clear that artificial intelligence is driving most of the market gains. Yet AI isn’t the only play right now, and multibaggers can be found in non-AI stocks too. Goldman Sachs, in its 2026 outlook, noted that reducing uncertainty around tariffs could boost economic security, aided by interest rate cuts. The firm stated:
“After a year dominated by tariff headlines, we expect the theme of economic security will be prominent in 2026, catalyzing large-scale capital deployment into defense, energy, and infrastructure across developed markets.”
When betting on stocks that have already delivered decent gains, a question investors often ask is whether they are investing at the peak. The S&P 500 index is set to register the third straight year of positive performance after a disappointing 2022. Morgan Stanley recently highlighted how the continued adoption of AI could lead to another productivity boom, similar to the one in the late 90s, when, after two positive years in 1995 and 1996, the market continued its upward momentum over the next 3 years as well. Such views support a constructive outlook for the coming months and strengthen the case for staying invested in the fundamentally strong, well-performing stocks that still offer substantial upside.
With that background, let’s explore our selection of 7 hidden multibagger stocks to invest in.
vichie81/Shutterstock.com
Our Methodology
To compile our list of 7 hidden multibagger stocks to invest in, we first looked at stocks that had returned at least 75% over the last year with a market capitalization of at least $1 billion. We then shortlisted stocks from this list with at least 30% potential upside. We then ranked the top 7 stocks in ascending order of their potential upside. We also included data on hedge fund holdings in these stocks as of Q3 2025 using Insider Monkey’s database.
7 Hidden Multibagger Stocks to Invest In
7. Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
Price Return over 1-Year: 264%
Potential Upside: 33%
Number of Hedge Fund Holders: 33
Praxis Precision Medicines Inc. (NASDAQ:PRAX) reported positive results from the registrational cohort of the EMBOLD study on December 4. This study is designed to examine relutrigine in patients diagnosed with SCN8A and SCN2A developmental and epileptic encephalopathies (DEEs). The trial was stopped earlier on the recommendation of the Data Monitoring Committee for efficacy.
President and Chief Executive Officer of PRAX, Marcio Souza, highlighted the importance of the positive outcome of the study by saying:
“SCN2A and SCN8A DEEs are devastating conditions with extremely high mortality due to the debilitating seizure burden they impose on patients, and there are currently no approved treatment options. Our progress represents an important milestone towards delivering the first therapy ever designed for these children and their families. We look forward to sharing the results at the American Epilepsy Society Annual Meeting.”
A meeting with the FDA has been scheduled to discuss next steps in the coming weeks. During the meeting, the data will also be reviewed.
On December 3, PRAX received a Buy rating from BTIG analyst Thomas Shrader. He assigned a target price of $424 to the stock.
Praxis Precision Medicines, Inc. develops therapies for central nervous system disorders. It operates as a clinical-stage biopharmaceutical company and has a license agreement with RogCon. The company also has a license agreement and research collaboration with Ionis Pharmaceuticals.
6. Solaris Resources Inc. (NYSEAMERICAN:SLSR)
Price Return over 1-Year: 139%
Potential Upside: 43.36%
Number of Hedge Fund Holders: 10
On Dec. 2, Maxim Group analyst Tate Sullivan reiterated his Hold rating on the stock. The rating comes after the stock has risen by 20% over the last month. This performance was aided by two back-to-back positive analyst ratings for the stock on November 7.
H.C. Wainwright first raised its price target to $13.5 from $13 on November 7. This announcement came after the company released pre-feasibility study results for its Warintza project. The flagship project is expected to produce 4.5 million tonnes of Copper Equivalent through its 22-year mine life. The exact breakdown of the estimates includes 3.4 million tonnes of Copper, 26.6 million ounces of Silver, and 1.1 million ounces of Gold.
On the same day as the above rating, BMO Capital also maintained its Buy rating on the stock.
As of December 5, Solaris Resources Inc. (NYSE:SLSR) enjoys highly positive analyst opinions with more than 85% of analysts covering it assigning a Buy or equivalent rating. With a consensus 1-year median price target of $11.04, the stock still reflects around 43% potential upside.
Solaris Resources Inc. (NYSE:SLSR) is a Canadian mineral exploration firm that is focused on commodities like copper, zinc, lead, silver, and gold. In addition to exploration, they also acquire and develop other mineral properties.
